DOI: 10.1159/000411633
|View full text |Cite
|
Sign up to set email alerts
|

New Drugs and New Delivery Techniques

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…These suggestions were proven valid by Tonn et al and Kleinschmidt-DeMasters et al, who demonstrated in treated patients a significant risk of local cerebral necrosis as well as leukoencephalopathy (116,120,121). Follow-ups of patients have shown that IA BNCU may result in leukoencephalopathy, blindness and increased risk of cerebral necrosis (10,116,(118)(119)(120)(121). The interest in IA nitrosourea derivatives began to wane after a randomised phase III trial comparing IA with IV BCNU showed that IA BCNU is unsafe and lacks effectiveness in regard to increasing patient survival (121).…”
Section: Nitrosourea Derivativesmentioning
confidence: 91%
See 1 more Smart Citation
“…These suggestions were proven valid by Tonn et al and Kleinschmidt-DeMasters et al, who demonstrated in treated patients a significant risk of local cerebral necrosis as well as leukoencephalopathy (116,120,121). Follow-ups of patients have shown that IA BNCU may result in leukoencephalopathy, blindness and increased risk of cerebral necrosis (10,116,(118)(119)(120)(121). The interest in IA nitrosourea derivatives began to wane after a randomised phase III trial comparing IA with IV BCNU showed that IA BCNU is unsafe and lacks effectiveness in regard to increasing patient survival (121).…”
Section: Nitrosourea Derivativesmentioning
confidence: 91%
“…First clinical studies of IA nitrosourea derivatives showed encouraging results, but the resulting neurotoxicity quickly diminished the enthusiasm (10,(116)(117)(118). In 1986, Feun and colleagues demonstrated in a follow-up phase II trial that IA BCNU may lead to severe leukoencephalopathy and blindness (119).…”
Section: Nitrosourea Derivativesmentioning
confidence: 99%
“…Cisplatin has been evaluated in recurrent glial tumors and in the treatment of a variety of pediatric brain tumors [3][4][5]. Some studies suggest efficacy and acceptable tolerance of the drug [6][7][8].…”
Section: Introductionmentioning
confidence: 99%
“…Despite the most recent advances in multi modality treatment of human malignant gliomas, the prognosis of these patients has not been significantly modified to date [1,2]. Considerable scope therefore remains for improving the therapy of patients with malignant brain tumors.…”
Section: Introductionmentioning
confidence: 99%